All News

The tribe recently issued its first medical cannabis card, marking a historic step in the state.

Ganjier's pioneering cannabis sommelier certification program, conducted both virtually and on its Humboldt County, California campus, is shaping a new generation of professionals who are set to elevate the standards and quality of cannabis products, filling a void that has long existed in the industry.

Legislation recently passed in the Australian state of Victoria will enable the testing of cannabis’ effects on driving safely.

A recent study conducted in Canada with over 1,200 participants has found that psilocybin may significantly alleviate psychological distress resulting from childhood trauma, particularly benefitting those with more severe adversity, suggesting its therapeutic potential in addressing long-lasting trauma-related symptoms.

A trailblazer in psilocybin studies, Dr. Roland Griffiths passed away at age 77 on October 16, 2023, of colon cancer.

The application window for cannabis business licenses in New York was extended.

The 18-month trial will study the effects of a cannabis extract as part of treatment for brain cancer.

Aurélien Rousseau, the Minister for Health of France, promises to roll out medical cannabis access to patients throughout the country.

Two senate bills, SB 302 and SB 700, were passed to California Governor Newsom where they were signed into law, expanding cannabis rights for both patients and employees.

A study found that cannabis users that were infected by the COVID-19 virus, experienced ‘better outcomes and mortality’ than non-cannabis users.

The ANA has formally announced their recognition of cannabis nursing as a specialty nursing practice.

A population-based, retrospective study looked at the associations between cannabis use and effects on heart health.

In Maine, a Portland City Council voted to partially decriminalize psychedelics.

Our sister publication, Contemporary Pediatrics, covered research published in the journal Pediatrics about the correlation between the degree of toxicity following pediatric ingestion of THC and the dose of THC.

The cannabis industry in Canada is suffering from product recalls due to harmful mold and mislabeling issues.

Various efforts to attract non-white participants to the study have not succeeded, putting the study in jeopardy.

One laboratory’s concerns lead to a closer look at Montana’s still-developing cannabis program.

The USDA has declared that it is safe to grow and breed hemp in the US.

Patient access to medical cannabis will increase greatly in the coming weeks.

Governor Gavin Newsom signs SB 622, a CannaCraft-sponsored bill, which will work to reduce plastic waste in the California cannabis industry.

Citing concerns with the increasing prevalence of cannabis in the country, the Prime Minister plans to curb ongoing legalization.

A recent study detailed how drug decriminalization did not increase the risk of overdose-related deaths.

The study’s principal investigator recently provided more information about the new trial compared to a previous one in 2017.

A study performed by Radicle Science showed how the MDSleep formulation can help benefit anxiety, sleep, stress, and overall well-being.

A new white paper provides in-depth analysis and recommendations to increase patient access to therapeutic psychedelics in Canada.

A2LA and NIHC have announced their partnership where they will start a joint recognition program for NIHC members and A2LA conformity assessment bodies.

Union College located in Union County, New Jersey, has partnered with Green Flower to create cannabis training programs to help meet with the industry’s workforce demand.

Accredited cannabis certification organization launches new standard focused on retail safety.

A panel of individuals from standards-setting organizations and accreditation bodies reviewed the role they each play within the cannabis sector and offered insights into the future of the industry to close out the analytical science track at Cannabis Science Conference Fall on Friday, September 22nd.

Our sister publication, Pharmacy Times, covered recent study results that could lead to an FDA approval for MDMA to treat post-traumatic stress disorder by the end of 2023.